| Literature DB >> 30560838 |
Chengliang Sun1, Guocui Xie2, Fei Huang3, Xukun Liu2.
Abstract
BACKGROUND Prostatic calculi are common in urological treatments. Our major purpose in the present study was to explore the occurrence and composition of prostatic calculi, and investigate the effect of calcium oxalate (CaOx) on clusterin expression and lower urinary tract symptom (LUTS) in prostatitis and benign prostatic hyperplasia (BPH) patients with calculi. MATERIAL AND METHODS From December 2016 to January 2017, a total of 79 prostatitis patients aged more than 50 years were enrolled. The patients were divided into 3 groups: group A had small calculi (discrete, small echoes); group B had large calculi (large masses of multiple echoes, much coarser), and group C had no calculi. Immunohistochemical analysis was performed to evaluate the tissue scores. The clusterin expression was detected by quantitative real-time CR (qRT-PCR), Western blot, and immunofluorescence. RESULTS According to multifactor analysis, age was significantly associated with prostatic calculus. The composition of prostatic calculus was an independent factor of LUTS. The clusterin expression was elevated in group B. The mRNA and protein levels of clusterin in prostatitis and BPH patients with stones were obviously higher than those in prostatitis and BPH patients without stones. CaOx enhanced clusterin expression in a dose-dependent manner. CONCLUSIONS Large prostatic calculi were associated with LUST. Furthermore, CaOx enhanced clusterin expression, leading to large prostatic calculi. These results may provide a therapeutic strategy for prostatitis and BPH.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30560838 PMCID: PMC6320640 DOI: 10.12659/MSM.911505
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Clinical parameters.
| Case | Control | ||
|---|---|---|---|
| Age (year) | 51.3±4.69 | 48.84±3.89 | 0.015 |
| BMI (Kg/m2) | 24.99±2.37 | 24.61±1.85 | 0.448 |
| PV (ml) | 26.18±5.57 | 24.06±5.23 | 0.09 |
| PSA (ng/ml) | 1.20±0.59 | 1.19±0.67 | 0.944 |
| IPSS | 9.87±5.97 | 7.50±4.1 | 0.08 |
| Severe LUTS | 0.142 | ||
| Yes | 27 | 13 | |
| No | 20 | 19 |
The effect of the composition of the prostate calculi on LUTS.
| Severe LUTS | Non-severe LUTS | ||
|---|---|---|---|
| CaOx | 23 | 12 | 0.05 |
| Non-CaOx | 4 | 8 |
Relationship between clinical parameters and clusterin expression in prostatitis and BPH patients.
| Clusterin expression | |||
|---|---|---|---|
| Positive | Negative | ||
| Case | 28 | 19 | 0.006 |
| Control | 9 | 23 | |
| Severe LUTS | 29 | 11 | <0.001 |
| Non-severe LUTS | 8 | 31 | |
Relationship between prostatic calculi component and clusterin expression in prostatitis and BPH patients with calculi.
| Clusterin expression | |||
|---|---|---|---|
| Positive | Negative | ||
| CaOx | 25 | 10 | 0.04 |
| Non-CaOx | 3 | 9 | |
| Severe LUTS | 22 | 5 | <0.001 |
| Non-severe LUTS | 6 | 14 | |
Figure 1Clusterin expression in prostate tissues. (A) Clusterin expression in patients with non-severe LUTS or severe LUTS. (a–c) Patients with non-severe LUTS; (d–f) Patients with severe LUTS. (B) The mean absorbance of clusterin in prostate tissues.
Figure 2Clusterin expression in the prostatitis and BPH patients. The mRNA (A) and protein levels (B) of clusterin in the prostatitis and BPH patients with and without calculi, respectively. P<0.0001.
Figure 3Clusterin expression in the RWPE-1 cells with CaOx treatment. The mRNA (A) and protein levels (B) of clusterin were enhanced by CaOx in a dose-dependent manner. ** P<0.01 versus the no-CaOx group.
Figure 4Clusterin expression was enhanced by CaOx in RWPE-1 cells. DAPI was used to visualize nuclei. Scale bar=20 μm.